CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

First patient dosed with DISP-10 in Dispatch Bio’s cancer trial

Phase 1DISP-10Positive
AI Analysis

Summary

Dispatch Bio has dosed the first patient in a Phase 1 trial evaluating DISP-10, an immunotherapy candidate, in advanced gastrointestinal cancers.

Clinical Trial Data

Phase

Phase 1

Patients

1

Importance:4/10
Sentiment:
0.30
immunotherapyPhase 1cancerGI cancertrial initiation
Related Companies

Read the original article

Published by Clinical Trials Arena on August 7, 2026 8:47 AM

Read Original